These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

568 related items for PubMed ID: 32216548

  • 1. Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors.
    Cabanillas ME, Dadu R, Iyer P, Wanland KB, Busaidy NL, Ying A, Gule-Monroe M, Wang JR, Zafereo M, Hofmann MC.
    Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548
    [Abstract] [Full Text] [Related]

  • 2. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
    Ofir Dovrat T, Sokol E, Frampton G, Shachar E, Pelles S, Geva R, Wolf I.
    Cancer Biol Ther; 2018 Sep; 19(10):871-874. PubMed ID: 30036146
    [Abstract] [Full Text] [Related]

  • 3. KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.
    Owen DH, Konda B, Sipos J, Liu T, Webb A, Ringel MD, Timmers CD, Shah MH.
    J Natl Compr Canc Netw; 2019 May 01; 17(5):409-413. PubMed ID: 31085763
    [Abstract] [Full Text] [Related]

  • 4. Case report: Complete response of an anaplastic thyroid carcinoma patient with NRAS Q61R/BRAF D594N mutations to the triplet of dabrafenib, trametinib and PD-1 antibody.
    Gui L, Zhu Y, Li X, He X, Ma T, Cai Y, Liu S.
    Front Immunol; 2023 May 01; 14():1178682. PubMed ID: 37122752
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAFV600E-mutated poorly differentiated thyroid cancer: A case report and review of the literature.
    Zeng Q, Deng Y, Zhang L, Wang W.
    Int J Clin Pharmacol Ther; 2022 May 01; 60(5):225-231. PubMed ID: 35072623
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.
    Hamidi S, Iyer PC, Dadu R, Gule-Monroe MK, Maniakas A, Zafereo ME, Wang JR, Busaidy NL, Cabanillas ME.
    Thyroid; 2024 Mar 01; 34(3):336-346. PubMed ID: 38226606
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer.
    Facchinetti F, Lacroix L, Mezquita L, Scoazec JY, Loriot Y, Tselikas L, Gazzah A, Rouleau E, Adam J, Michiels S, Massard C, André F, Olaussen KA, Vassal G, Howarth K, Besse B, Soria JC, Friboulet L, Planchard D.
    Eur J Cancer; 2020 Jun 01; 132():211-223. PubMed ID: 32388065
    [Abstract] [Full Text] [Related]

  • 13. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
    Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ, Sherman SI.
    Thyroid; 2013 Oct 01; 23(10):1277-83. PubMed ID: 23489023
    [Abstract] [Full Text] [Related]

  • 14. Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in BRAFV600E Papillary Thyroid Carcinoma.
    Valvo V, Iesato A, Kavanagh TR, Priolo C, Zsengeller Z, Pontecorvi A, Stillman IE, Burke SD, Liu X, Nucera C.
    Thyroid; 2021 Sep 01; 31(9):1335-1358. PubMed ID: 33107403
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. BRAFV600E Overrides NOTCH Signaling in Thyroid Cancer.
    Traversi F, Stooss A, Dettmer MS, Charles RP.
    Thyroid; 2021 May 01; 31(5):787-799. PubMed ID: 33012268
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma.
    Chen TY, Lorch JH, Wong KS, Barletta JA.
    Histopathology; 2020 Aug 01; 77(2):314-320. PubMed ID: 32428249
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.